Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.
Volume: 39, Issue: 15_suppl, Pages: 7013 - 7013
Published: May 20, 2021
Abstract
7013 Background: The phase 3 ADMIRAL trial demonstrated the superiority of gilteritinib to salvage chemotherapy (SC) in patients (pts) with FLT3-mutated ( FLT3 mut+ ) R/R AML. Aim/Objective: A follow-up of ADMIRAL assessed long-term survivors, transplant (HSCT) outcomes. and gilteritinib safety beyond 1 year. Methods: A data cut was performed on September 20, 2020—2 years after the primary analysis. Patients who were alive without relapse, pts...
Paper Details
Title
Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.
Published Date
May 20, 2021
Journal
Volume
39
Issue
15_suppl
Pages
7013 - 7013
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History